MaxCyte Inc(MXCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.33 | Insider Own | 8.12% | Shs Outstand | 106.1M | Perf Week | 16.33% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | 6.91% | Insider Trans | - | Shs Float | 94.8M | Perf Month | 44.92% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.08 | Inst Own | 65.44% | Short Float | 1.93% | Perf Quarter | 62.86% |
| Income | -0.04B | P/S | 5.68 | EPS this Y | 34.78% | Inst Trans | -0.91% | Short Ratio | 2.1 | Perf Half Y | 109.15% |
| Sales | 0.03B | P/B | 1.14 | EPS next 5Y | 17.03% | ROA | -17.62% | Short Interest | 1.83M | Perf YTD | 10.32% |
| Book/sh | 1.5 | P/C | 1.67 | EPS past 3/5Y | -21.85% -19.78% | ROE | -20.39% | 52W High | -5.26% ($1.80) | Perf Year | 10.32% |
| Cash/sh | 1.02 | P/FCF | - | Sales past 3/5Y | -9.3% 4.76% | ROIC | -20.42% | 52W Low | 165.78% ($0.64) | Perf 3Y | -41.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.12% | Gross Margin | 66.17% | Volatility(W/M) | 9.51% 6.96% | Perf 5Y | -84.18% |
| Dividend TTM | - | EV/Sales | 2.84 | Sales Y/Y TTM | -13.15% | Oper. Margin | -103.98% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.47 | EPS Q/Q | 28.42% | Profit Margin | -114.77% | RSI (14) | 78.21 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.26 | Sales Q/Q | -14.53% | SMA20 | 36.8% ($1.25) | Beta | 1.56 | Target Price | $4.11 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/11/10 | SMA50 | 37.27% ($1.25) | Rel Volume | 1.96 | Prev Close | $1.54 |
| Employees | 91 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | 11.11% 11.75% | SMA200 | 61.45% ($1.06) | Avg Volume(3M) | 0.87M | Price | $1.71 |
| IPO | 2019/12/5 | Option/Short | Yes/Yes | Trades | 6137 | Volume | 1,709,300 | Change | 11.04% |
🧬 MaxCyte is a U.S. life sciences tools company that supplies electroporation-based cell engineering equipment and consumables for cell manipulation. It provides intracellular delivery platforms to cell and gene therapy developers and biopharmaceutical companies, generating revenue through equipment sales, consumables, and licensing partnerships. The company serves as a critical piece of infrastructure for cell therapy research and commercialization workflows.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded more than usual. That is 196% of its average volume.
Next earnings report: November 10
12 days to go.
MXCT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +34.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $568. Peers typically go for $154.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 65.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #79 of 142 in the industry
Based on market cap of $176M.
RXST#77 RxSight Inc $204M PER - 
INGN#78 Inogen Inc $192M PER - MXCT#79 MaxCyte Inc $176M PER - 
STIM#80 Neuronetics Inc $172M PER - 
QTRX#81 Quanterix Corp $148M PER - 
FAQ
What kind of company is MXCT?
MXCT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of MXCT?
The market cap of MXCT is approximately $176M, ranking 4,117 within its sector.
What is the 52-week high and low for MXCT?
MXCT has recorded a 52-week high of $1.80 and a low of $0.64.
